PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024GlobeNewsWire • 07/31/24
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 TrialGlobeNewsWire • 06/10/24
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/08/24
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsGlobeNewsWire • 04/30/24
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024GlobeNewsWire • 04/24/24
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 02/19/24
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/14/24
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialGlobeNewsWire • 02/12/24
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024GlobeNewsWire • 01/31/24
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/08/23
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of DirectorsGlobeNewsWire • 11/07/23
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023GlobeNewsWire • 11/01/23
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023GlobeNewsWire • 10/09/23
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology PlatformGlobeNewsWire • 10/04/23
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/22/23